SAVE THE DATE: First International Symposium on Functional and Clinical Aspects of the Tumour Antigen CA-IX to be held on 14 November 2007 in Brussels
MUNICH, Germany, 3 July 2007. The first international symposium on functional and clinical aspects of the tumour antigen "Carbonic Anhydrase IX" (or CA-IX) will be held on 14 November 2007. The symposium will report on the latest research findings and clinical developments relating to CA-IX in the areas of diagnosis, prognosis and therapy.
The event is co-sponsored by the Munich-based biopharmaceutical company WILEX AG (ISIN DE0006614720 / Frankfurt Stock Exchange / Prime Standard) and the international Ludwig Institute for Cancer Research (LICR). It will be held in the Sheraton Hotel in Brussels and participation is free of charge.
Tumour antigens such as CA-IX are becoming increasingly important in the diagnosis and treatment of cancer. CA-IX is the most specific antigen known for clear cell renal cell carcinomas, for example and its potential importance in other tumour types is beginning to be recognised. WILEX AG has developed a monoclonal antibody (WX-G250, development name RENCAREX®) which specifically binds to the CA-IX antigen. The drug candidate RENCAREX® is currently in a clinical Phase III trial to prevent the development of metastatic disease in kidney cancer patients following partial or complete removal of the affected kidney.
If you have any further questions, please do not hesitate to contact us.
Manager Public Relations
Tel.: +49 (0)89-41 31 38-29
Fax: +49 (0)89-41 31 38-99
WILEX AG | Grillparzerstraße 10, 81675 München, Deutschland, Tel. +49 (0) 89 413138-0, Fax +49 (0) 89 413138-99, firstname.lastname@example.org, www.wilex.com <http://www.wilex.com/> | Vorstand: Prof. Dr. Olaf G. Wilhelm (Vorsitzender), Dr. Paul Bevan, Peter Llewellyn-Davies | Vorsitzender des Aufsichtsrates: Dr. David R. Ebsworth | Sitz der Aktiengesellschaft: München, Amtsgericht München, HRB 136670 | HypoVereinsbank München, BLZ 700 202 70, Kto. 5800225304 | Deutsche Bank München, BLZ 700 700 10, Kto. 1616150
Diese E-Mail ist eine persoenliche Nachricht und enthaelt moeglicherweise vertrauliche Informationen. Sollten Sie nicht der bestimmungsgemaesse Empfaenger oder dessen Vertreter sein, so bitten wir Sie, diese E-Mail weder zu lesen, noch zu kopieren, noch in sonstiger Form zu verwenden und sie auch anderen nicht bekannt zu geben. Bitte benachrichtigen Sie den Absender von dem Zustellungsfehler, indem Sie eine Antwortnachricht senden und loeschen Sie diese E-Mail dann aus Ihrem System. Vielen Dank.
This e-mail message is a private communication and may contain confidential information. If you are not the intended recipient or the representative, please do not read, copy, or use this e-mail message, and do not disclose it to others. Please notify the sender of the delivery error by replying to this e-mail message, and then delete it from your system. Thank you.
WILEX is a biopharmaceutical Company based in Munich founded in 1997 by a team of physicians and oncologists from the Technical University of Munich. WILEX is focused on the development of new cancer therapies based on antibodies and small molecules. The therapeutic approach of WILEX targets the prevention of growth, spread and the metastasis of malignant tumours and the destruction of malignant tumours in the body. The late stage multi-product portfolio includes both drug and medicinal product candidates ranging from research to late stage clinical development. Currently the following compounds are in clinical development: WX-G250 (development name: RENCAREX®), WX-671, WX-UK1 and CA9-SCAN. The Company's strategy is to develop WILEX into a commercially successful biopharmaceutical company with a broad portfolio of new drugs and medical products for the treatment of cancer. WILEX AG has been listed at the Frankfurt Stock Exchange on the Official Market Segment (Amtlicher Markt) / Prime Standard since 13 November 2006.
ISIN DE0006614720 / WKN 661472 / Symbol WL6
The Ludwig Institute for Cancer Research (LICR) is the largest international non-profit institute dedicated to understanding and controlling cancer. With operations at 73 sites in 17 countries, LICR's research network quite literally spans the globe. LICR has developed an impressive portfolio of reagents, knowledge, expertise, and intellectual property, and has also assembled the personnel, facilities, and practices necessary to patent, clinically evaluate, license, and thus translate, the most promising aspects of its own laboratory research into cancer therapies.
Sarah L. White, Ph.D.
Director, Office of Communications
605 Third Avenue / 33rd Floor
New York, NY 10158
Tel: +1 917 379 0398
Fax: +1 212 450 1500
Posted: July 2007